Simvastatin Enhances Clinical Response to Sulfadoxine-Pyrimethamine in Falciparum Malaria

Ndubuisi N. Nwobodo¹* and Paul O. Okonkwo²

¹Department of Pharmacology & Therapeutics, Ebonyi State University, Abakaliki, Nigeria.
²Department of Pharmacology & Therapeutics, University of Nigeria.

doi: http://dx.doi.org/10.13005/bbra/1524

(Received: 30 October 2014; accepted: 06 December 2014)

Doubts have been raised concerning the therapeutic efficacy of sulfadoxine-pyrimethamine due to poor clinical response necessitating the need for continuous monitoring and further advocating for the replacement of sulfadoxine-pyrimethamine with suitable alternatives. Indeed, the therapeutic life of sulfadoxine-pyrimethamine was predicted to last for only five years following its introduction in Africa as alternative to chloroquine, due to high transmission rates of

A study raised doubts about the therapeutic efficacy of sulfadoxine-pyrimethamine due to poor clinical response, necessitating the need for continuous monitoring and further advocated the replacement of sulfadoxine-pyrimethamine with suitable alternatives¹. Indeed, the therapeutic life of sulfadoxine-pyrimethamine was predicted to last for only five years following its introduction in Africa as alternative to chloroquine, due to high transmission rates of
malaria. Sulfadoxine-pyrimethamine has been recommended by World Health Organisation (WHO), for intermittent preventive therapy (IPT) in pregnancy, particularly in the disease endemic zones. A study hypothesized that combination of molecular and epidemiological factors may be implicated in the clinical efficacy of sulfadoxine-pyrimethamine. The declining clinical efficacy and parasite clearance rates, all point to the dire need for novel effective treatment of malaria infection. A number of mechanisms acting through various organ systems are involved in the pathophysiology of malaria infection. Statins are known to down regulate biosynthesis of dolichol and isoprenoid pyrophosphate, inhibiting in vitro growth of Plasmodium falciparum. A study revealed that the clinical benefit of statins could be attributed not only to improvement in endothelial function, but a significant reduction in anti-inflammatory effects. Simvastatin has been shown to reduce tumor necrosis factor-α (TNF-α), Interleukin-1 (IL-1) and pro-inflammatory cytokines. The production of TNF-α and IL-1 is induced by glycosylphosphatidylinositol (GPI) produced by Plasmodium falciparum, leading to TNF-α induced weight loss in malaria infection. Consequently, the present study was aimed at evaluating the clinical response of simvastatin plus sulfadoxine-pyrimethamine (test group) combination as compared to sulfadoxine-pyrimethamine alone (control group) in the chemotherapy of malaria.

MATERIALS AND METHODS

Subjects

The subjects selected for this study were patients in attendance at primary health facilities (n=60) suffering from malaria infection, diagnosed using thick blood films and confirmed by immunological test (Paracheck PI®). A rapid qualitative two site sandwich immunochromatographic dipstick assay, (Paracheck PI®), was employed for the determination of Plasmodium falciparum specific histidine rich protein-2 (PfHRP-2) in whole blood samples. This was in view of the fact that classical method of diagnosis by microscopy involving examination of thin and thick blood smears was time consuming and prone to false negative readings.

Study Design

Formal written documentation was employed in obtaining informed consent after adequate explanation of the purpose of study, type of treatment to be administered and clarification of any likely adverse effects or complication that may arise in the course of treatment. Patients within the age range 16 to 65 years inclusive attending eight primary health facilities within Asu Nkanu Local Health Authority in Nkanu East Local Government Area of Enugu State, Nigeria were selected for the study. The subject’s physical condition and presence of any confounding ailment were ascertained following routine clinical clerkship and examination including body weight measurement and axillary temperature. Subjects were randomised into test and control groups using a table of random numbers statistically generated. The principal investigator, microscopist, field supervisor, field assistants, medical officer, nurses and all other participants in the study did not have any prior knowledge of the patients’ medical records nor the treatment group to which each subject was assigned. The Health Research Ethics Committee, University of Nigeria Teaching Hospital Ituku-Ozalla, Nigeria provided ethical clearance certification (Ref: NHREC/05/01/2008B) in line with principles guiding human experimentation as enumerated in the Declaration of Helsinki by the World Medical Association General Assembly as last amended (Seoul 2008); while Enugu State Ministry of Health, Nigeria provided approval for this study. Sulfadoxine-pyrimethamine (Fansidar® from Swiss Pharma, Lagos-Nigeria) was given as stat dose of 25mg/kg for the Sulfadoxine component and 1.25mg/kg for the other component Pyrimethamine. Each tablet of Sulfadoxine-Pyrimethamine contains 500mg Sulfadoxine and 25mg Pyrimethamine. Simvastatin (Simvor® from Ranbaxy Laboratories, Dewas, Nigeria) was given orally in the dosage 0.6mg/kg/d only in the evening for 3 consecutive days. The control group received Sulfadoxine-pyrimethamine only in same dose as test group. Patients who presented with treatment failure or recrudescence were salvaged with Artemether-Lumefantrine (Coartem® from Novartis Pharma AG, Basel-Switzerland); and eventually withdrawn from the study. The Artemether component was given as 3.2mg/kg/d while the Lumefantrine as 19.2 mg/kg/d respectively in two
divided doses for 3 days. Baseline monitoring of liver function tests was done before commencement and in the course of therapy. Elevation of serum transaminase activity up to three times normal level will result to discontinuation of simvastatin.

Assessment of Response

The patients were followed up on days D0, D3, D7, D14 and D28. The World Health Organisation (WHO) criteria were applied in the categorization of therapeutic response as follows:

**Early Treatment Failure (ETF)**
Development of danger signs of severe malaria on D1-D3 in the presence of parasitemia. Parasitemia on D2 higher than D0 count irrespective of axillary temperature. Parasitemia on D3 with axillary temperature > 37.5°C.

**Late Treatment Failure (LTF)**
Development of danger signs of severe malaria after D3 in the presence of parasitemia, without previously meeting any of the criteria of early treatment failure. Presence of parasitemia and axillary temperature > 37.5°C on any day from D4 to D14, without previously meeting any of the criteria of early treatment failure.

**Late Parasitological Failure (LPF)**
Presence of parasitemia on D28 and axillary temperature < 37.5°C without previously meeting any of the criteria of early treatment failure or late treatment failure.

**Adequate Clinical and Parasitological Response (ACPR)**
Absence of parasitemia on D14 irrespective of axillary temperature without previously meeting any of the criteria of early treatment failure or late treatment failure.

**Fever Clearance Time (FCT)**
The time taken from anti-malarial drug administration until axillary temperature falls below 37.4°C and remains at that value for 72 hours.

**Parasite Clearance Time (PCT)**
The time taken from anti-malarial drug administration until no patent parasitemia is detected.

**Clinical Clearance Rate (CCR):** The proportion of subjects with full resolution of signs and symptoms of malaria on D14.

**Recrudescence Rate (RR):** The proportion of subjects in which there is incomplete clearance of parasitemia on D14 and D28 of follow-up.

**Statistical analysis**
The analysis of data was facilitated using Graphpad Prism version 4.0 (GraphPad Software, Inc., La Jolla, CA, USA) statistical software and data presented in tabular and graphical forms. Statistical test of significance ascertained using two-tailed Student t-test, assuming p<0.05 considered significant at 95% confidence interval.

**RESULTS**

Table 1 depicts the baseline characteristics of test and control groups at presentation.

Table 2 shows mean values of treatment failure in patients treated with sulfadoxine-pyrimethamine and simvastatin (test) and those treated with sulfadoxine-pyrimethamine alone.

### Table 1. Baseline Characteristics of Test and Control Groups

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Test</th>
<th>Control</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Patients</td>
<td>30</td>
<td>30</td>
<td>-</td>
</tr>
<tr>
<td>Male: Female Ratio</td>
<td>2:3</td>
<td>2:3</td>
<td>-</td>
</tr>
<tr>
<td>Mean Age (Range: 16-65 years)</td>
<td>41.7±2.5</td>
<td>38.2±2.6</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>Mean Weight (Range: 43–92 kg)</td>
<td>60.8±3.7</td>
<td>63.4±3.2</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>Mean Temperature (Range: 37.8–39.2°C)</td>
<td>39.2±1.9</td>
<td>38.0±1.6</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>Mean Parasite Density (Range: 1260-21500/µL)</td>
<td>9635±791</td>
<td>8791±750</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>Mean Hemogram (Range: 4.2 – 11.5 g/dL)</td>
<td>8.2±1.3</td>
<td>7.9±1.0</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>Mean WBC Total (Range: 3000 – 11700 x 10⁹/L)</td>
<td>6955±452</td>
<td>7470±455</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>Mean Alanine Transaminase (Range: 7.8-31.2 U/L)</td>
<td>14.8±3.5</td>
<td>15.6±4.3</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>Mean Aspartate Transaminase (Range: 13.7-28.4 U/L)</td>
<td>15.8±4.6</td>
<td>17.3±4.8</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>Mean Alkaline Phosphatase (Range: 45.2-110.7 U/L)</td>
<td>85.1±7.9</td>
<td>79.6±7.7</td>
<td>p&gt;0.05</td>
</tr>
<tr>
<td>Mean Total Bilirubin (Range 4.3-13.8 μmol/L)</td>
<td>8.7±1.4</td>
<td>9.1±1.4</td>
<td>p&gt;0.05</td>
</tr>
</tbody>
</table>
Table 2. Mean treatment failure in the test and control groups

<table>
<thead>
<tr>
<th>Treatment Parameters</th>
<th>Test</th>
<th>Control</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETF (%)</td>
<td>9.2±0.26</td>
<td>20.5±0.26</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>LTF (%)</td>
<td>10.3±0.15</td>
<td>23.6±0.22</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>ACPR (%)</td>
<td>77.5±0.59</td>
<td>55.9±0.49</td>
<td>P&lt;0.05</td>
</tr>
</tbody>
</table>

ETF: Early Treatment failure
LTF: Late Treatment failure
ACPR: Adequate Clinical and Parasitological Response

Table 3. Mean clinical response in the test and control groups

<table>
<thead>
<tr>
<th>Clinical Parameters</th>
<th>Test</th>
<th>Control</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCT (Days)</td>
<td>4.4±0.2</td>
<td>9.8±0.2</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>FCT (hours)</td>
<td>55.3±2.6</td>
<td>87.4±4.5</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>CCR (%)</td>
<td>82.3±0.8</td>
<td>60±1.3</td>
<td>P&lt;0.05</td>
</tr>
<tr>
<td>RR (%)</td>
<td>19.1±0.14</td>
<td>39±0.22</td>
<td>P&lt;0.05</td>
</tr>
</tbody>
</table>

PCT: Parasite Clearance Time
FCT: Fever Clearance Time
CCR: Clinical Clearance Rate
RR: Recrudescence Rate

Results revealed a statistically significant difference (p<0.05) in declining parasitemia days 0, 3, 7, 14 and 28 between test and control groups as shown in Figure 1. A study reported values of 5% and 18% as proportion of initial parasitemia at days 14 and 28 respectively in patients treated with sulfadoxine-pyrimethamine alone. The same study reported that 77% of the patients achieved complete parasite clearance by day 3 after enrollment and treatment with sulfadoxine-pyrimethamine. A study had emphasized the use of mean geometric gametocyte densities in assessment of response to sulfadoxine-pyrimethamine. That study attempted to evaluate the effects of sulfadoxine-pyrimethamine on gametocyte generation during treatment to determine whether or not sulfadoxine-pyrimethamine will influence the generation of gametocytemia and to evaluate peripheral young follow-up days D0, D3, D7, D14 and D28 are as shown in Figure 1. Figure 1 depicts the mean geometric parasite densities of the test and control groups on follow-up days D0, D3, D7, D14 and D28.

**DISCUSSION**

Fig. 1. Depicts linear graphical representation of the progressive decline in the level of parasitemia in both test and control groups treated with sulfadoxine-pyrimethamine. It revealed mean geometric parasite density of 9635/µL, 2971/µL, 1076/µL, 217/µL and 13/µL for days 0, 3, 7, 14 and 28 respectively in the test group. This is as compared to the mean geometric parasite density of 8791/µL, 4098/µL, 1934/µL, 650/µL and 326/µL reported in the control group.
gametocytes (PYG) as an indicator of response to therapy.

It has already been documented that sulfadoxine-pyrimethamine may or may not enhance gametocyte carriage during treatment of acute falciparum infections\(^\text{13,14}\). Notwithstanding, that the presence of gametocytes in peripheral blood after anti-malarial treatment was no proof of viability, their generation was required for the transmission of the infection from the vertebrates to the anopheline host. Instructively, it was not clear whether the enhancement or non-enhancement of gametocyte production by sulfadoxine-pyrimethamine will be influenced by its use in combination with statins. However, it has been shown that peripheral young gametocytes (PYG) were not an indicator of response to sulfadoxine-pyrimethamine, since both sulfadoxine-pyrimethamine sensitive and resistant infections generated peripheral young gametocytes. Thus, the non-determination of gametocyte carriage status may not necessarily be considered a limitation in the present study. This study reported a relatively higher therapeutic failure in the control compared to test group treated with sulfadoxine-pyrimethamine as shown in Table 2. A total treatment failure of 36.4% was reported in a study in South-East Nigeria\(^\text{15}\). Again, there was relatively better clinical response in the test group compared to control as evidenced by ACPR (Adequate Clinical and Parasitological Response) of 77.5% and 55.9% respectively. The total treatment failure of 19.5% in the test group treated with sulfadoxine-pyrimethamine was considered below the 25% limit recommended for centers in the high endemicity of malaria transmission. The early treatment failure (ETF) rate of 9.2% reported in the test group was still below the 10% margin recommended for change in first line anti-malarial therapy as compared to 20.5% in the control. Consequently, the continuous use of sulfadoxine-pyrimethamine will create an apparent well-being but engender a tendency to chronic malaria morbidity in the study population particularly the control.

The World Health Organization has consistently recommended to malaria control programs in Africa to rely more on clinical rather than parasitological response in assessment of anti-malarial efficacy. The widespread decline in chloroquine efficacy three decades ago, then necessitated many African countries to adopt sulfadoxine-pyrimethamine as first line therapy in treatment of uncomplicated falciparum malaria. However, progressive decline in sensitivity of \textit{Plasmodium falciparum} to sulfadoxine-pyrimethamine had since been reported\(^\text{16,17}\). The mean fever clearance time (FCT) in this study is as given in Table 3. This was as compared to 33.6 hours reported in an earlier study\(^\text{18}\). However, recent studies in South-West and South-East Nigeria revealed fever clearance time of 52.8 and 74.6 hours respectively in subjects treated with sulfadoxine-pyrimethamine alone, which corroborated results in the present study\(^\text{12,19}\). The fever clearance time of 33.6 hours and parasite clearance time of 3.9 days obtained in a previous study differed significantly from the values obtained in control group treated with sulfadoxine-pyrimethamine in the present study. This was not surprising as the previous study was carried out over a decade ago when clinical response to sulfadoxine-pyrimethamine was far more reliable. The mean parasite clearance time (PCT) reported for this study is as shown in Table 3. This was as compared to a recent study which reported parasite clearance time of 6.1 days in subjects treated with sulfadoxine-pyrimethamine alone\(^\text{19}\). The time to 50% and 90% clearance (PC\(_{50}\) and PC\(_{90}\)) for the said study were given as 0.82 and 1.12 days respectively. It further highlighted that indices of therapeutic response estimated by conventional methods, that is time to 50% or 90% reduction of parasitemia and parasite clearance time, were sufficiently higher than those derived from the corresponding functional viability estimate \textit{ex vivo} for sulfadoxine-pyrimethamine. However, the conventional method employed in the present study was unable to differentiate viable from non-viable circulating parasites\(^\text{20}\).

The recrudescence rates reported in this study were 19.1% and 39% in the test and control groups respectively treated with sulfadoxine-pyrimethamine. However, clinical clearance rate of 82.3% and 60% were reported in the present study for the test and control groups respectively. The above values correlated with cure rate of 74.5% and 55.9% reported for the test and control groups respectively in this study.

The trophozoite stage of malaria parasite which is analogous to \textit{G}\(_1\) phase of the mammalian
The G₀ phase of mammalian cell cycle is related to the early ring stage which can develop in vitro in the absence of serum components²¹. The re-initiation of parasite development shows strong similarities to the proliferation of mammalian cells in the G₀ phase after stimulation with lipoproteins²². The traversal of the cellular barrier between liver cells and the circulatory system is a crucial step in malaria infection. Hence, targeting the liver with statins could be a very effective strategy for novel malaria treatment and prevention. In conclusion, the enhancement of clinical response to sulfadoxine-pyrimethamine in the present study is attributable to the modulating influence of the HMG-CoA reductase inhibitor, simvastatin.

ACKNOWLEDGMENTS

I wish to acknowledge the immense contribution of Mr. M.O. Offu and the entire staff of 8 primary health facilities in the study site within Asu-Nkanu Local Health Authority. Indeed, worthy of mention is Prof. Eddy Nwobodo, formerly, Dean, Faculty of Basic Medical Sciences, Nnamdi Azikiwe University for his useful advice and contribution. The selfless contribution of Dr. Nick C. Obitte, Lecturer, Department of Pharmaceutical Technology, University of Nigeria, Nsukka is highly appreciated. I acknowledge with gratitude the selfless assistance of Mr. E.A. Aguodoh, of the Department of Hematology, University of Nigeria Teaching Hospital, Ituku-Ozalla and Mr. Chuks Ihionu, Director, McChuks Laboratory, Enugu.

REFERENCES


